Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 16, 2009Journal of Nuclear MedicineOpen Access

Prognostic Value of Interim 18F-FDG PET in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment at 4 Cycles of Chemotherapy

View Full Paper
Ask AI
Bookmark
Share

Authors

EIEmmanuel IttiCentre Hospitalier Universitaire Henri-MondorCLChieh LinChang Gung Memorial HospitalJDJehan DupuisInserm

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Itti et al. (2009) studied this question.

synapsesocial.com/papers/6a950a0da9fda6dc960f387dhttps://doi.org/10.2967/jnumed.108.057703
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Whole-Body Positron Emission Tomography Using18F-Fluorodeoxyglucose for Posttreatment Evaluation in Hodgkin’s Disease and Non-Hodgkin’s Lymphoma Has Higher Diagnostic and Prognostic Value Than Classical Computed Tomography Scan Imaging1999 · 557 citations
  2. 2FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma2005 · 725 citations
  3. 3Prognostic Value of Positron Emission Tomography (PET) With Fluorine-18 Fluorodeoxyglucose ([<sup>18</sup>F]FDG) After First-Line Chemotherapy in Non-Hodgkin’s Lymphoma: Is [<sup>18</sup>F]FDG-PET a Valid Alternative to Conventional Diagnostic Methods?2001 · 465 citations
  4. 4Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose.1998 · 338 citations
  5. 5FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma2008 · 65 citations